IOCAS-IR  > 实验海洋生物学重点实验室
Fucoidan, as an immunostimulator promotes M1 macrophage differentiation and enhances the chemotherapeutic sensitivity of capecitabine in colon cancer
Deng, Zhenzhen1,2,3,4; Wu, Ning1,2,5; Suo, Qishan2,4; Wang, Jing1,2,3; Yue, Yang1,2,3; Geng, Lihua1,2,3; Zhang, Quanbin1,2,3
2022-12-01
发表期刊INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
ISSN0141-8130
卷号222页码:562-572
通讯作者Wu, Ning(wuning@qdio.ac.cn) ; Zhang, Quanbin(qbzhang@qdio.ac.cn)
摘要Chemotherapy resistance is one of the most critical challenges in colorectal cancer (CRC) treatment. The occurrence and development of chemotherapy resistance closely related to the tumor immune microenvironment (TIME). As the most important immunosuppressive immune cells infiltrating into the TIME, macrophages are essential for chemotherapy resistance in CRC treatment. In this study, we found that a kind of fucoidan (FPS1M) induced macrophages differentiation to the M1 phenotype, and this transformation promoted cancer cells apoptosis both in vitro and in vivo. TNF alpha is a key mediator of FPS1M-induced tumorcidal activity of macrophages. Mechanistically, as a stimulator of TLR4, FPS1M enhanced macrophages glycolysis and regulated macrophages differentiation to the M1 phenotype by the activation of TLR4 mediated PI3K/AKT/mTOR signaling axis. In addition, FPS1M improved the immunosuppressed tumor microenvironment by increasing the infiltration of M1 macrophages in tumor tissue, which was conducive to improving the sensitivity of tumor to chemotherapy. Collectively, our findings demonstrated that FPS1M has the great potential to be used in tumor immunotherapy. The results also suggested that the combination of FPS1M with capecitabine is an alternative therapy method for colon cancer.
关键词Capecitabine Tumor microenvironment Macrophages TLR4 Fucoidan
DOI10.1016/j.ijbiomac.2022.09.201
收录类别SCI
语种英语
资助项目National Natural Science Foundation of China ; Major Scientific & Engineering Projects of Innovation in Shandong Province ; [81872906] ; [42176137] ; [2019JZZY010818]
WOS研究方向Biochemistry & Molecular Biology ; Chemistry ; Polymer Science
WOS类目Biochemistry & Molecular Biology ; Chemistry, Applied ; Polymer Science
WOS记录号WOS:000876352600006
出版者ELSEVIER
引用统计
被引频次:15[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.qdio.ac.cn/handle/337002/180540
专题实验海洋生物学重点实验室
通讯作者Wu, Ning; Zhang, Quanbin
作者单位1.Chinese Acad Sci, CAS, Qingdao 266071, Peoples R China
2.Chinese Acad Sci, Inst Oceanol, Ctr Ocean Mega Sci, Shandong Prov Key Lab Expt Marine Biol, Qingdao 266071, Peoples R China
3.Qingdao Natl Lab Marine Sci & Tech, Lab Marine Biol & Biotechnol, Qingdao 266071, Peoples R China
4.Univ Chinese Acad Sci, Beijing 100049, Peoples R China
5.Pilot Natl Lab Marine Sci & Technol, Lab Marine drugs & Biol Prod, Qingdao, Peoples R China
第一作者单位中国科学院海洋研究所
通讯作者单位中国科学院海洋研究所
推荐引用方式
GB/T 7714
Deng, Zhenzhen,Wu, Ning,Suo, Qishan,et al. Fucoidan, as an immunostimulator promotes M1 macrophage differentiation and enhances the chemotherapeutic sensitivity of capecitabine in colon cancer[J]. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES,2022,222:562-572.
APA Deng, Zhenzhen.,Wu, Ning.,Suo, Qishan.,Wang, Jing.,Yue, Yang.,...&Zhang, Quanbin.(2022).Fucoidan, as an immunostimulator promotes M1 macrophage differentiation and enhances the chemotherapeutic sensitivity of capecitabine in colon cancer.INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES,222,562-572.
MLA Deng, Zhenzhen,et al."Fucoidan, as an immunostimulator promotes M1 macrophage differentiation and enhances the chemotherapeutic sensitivity of capecitabine in colon cancer".INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES 222(2022):562-572.
条目包含的文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
1-s2.0-S014181302202(8782KB)期刊论文出版稿限制开放CC BY-NC-SA浏览
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Deng, Zhenzhen]的文章
[Wu, Ning]的文章
[Suo, Qishan]的文章
百度学术
百度学术中相似的文章
[Deng, Zhenzhen]的文章
[Wu, Ning]的文章
[Suo, Qishan]的文章
必应学术
必应学术中相似的文章
[Deng, Zhenzhen]的文章
[Wu, Ning]的文章
[Suo, Qishan]的文章
相关权益政策
暂无数据
收藏/分享
文件名: 1-s2.0-S0141813022021389-main.pdf
格式: Adobe PDF
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。